Title: 105 CMR 720
Author: EOHHS
Company: Commonwealth of Massachusetts

105 CMR:   DEPARTMENT OF PUBLIC HEALTH

105 CMR:   DEPARTMENT OF PUBLIC HEALTH

720.200:   continued

105 CMR 720.000:		LIST OF INTERCHANGEABLE DRUG PRODUCTS

Section

720.001:   Purpose
720.002:   Citation
720.010:   Scope and Application
720.020:   Definitions

Standards
720:040:   Commission Review of Relevant Drug Products
720.050:   List of Interchangeable Drug Products 
720.060:   Drug Products Excluded
720.070:   Amendments to the Massachusetts List of Interchangeable Drugs

Procedures for Amending List of Interchangeable Drug Products
720.080:   Procedures for Amending the Massachusetts List of Interchangeable Drugs
720.081:   Petition to Amend List of Interchangeable Drug Products
720.082:   Commission Review of Petition
720.083:   Notice of Public Comment Period
720.084:   Commission Recommendation of Amendments to Department
720.090:   Department Adoption of Amendments
720.100:   Severability
720.200:   Appendix A:  List of Interchangeable Drugs

720.001:   Purpose

The purpose of 105 CMR 720.000 is to establish a drug formulary, or list of interchangeable drug products, for use by physicians, other practitioners, and pharmacists licensed to practice within the commonwealth, so that consumers of prescription drug products may realize cost savings by buying less expensive, safe drug products.

720.002:   Citation

105 CMR 720.000 shall be known as the 105 CMR 720.000:  Massachusetts List of Interchangeable Drug Products.

720.010:   Scope and Application

105 CMR 720.000 establishes the list of interchangeable drug products from which a pharmacist must interchange a reasonably available less expensive drug product than that written, when a prescription written by a practitioner indicates "interchange". 105 CMR 720.000 also establishes criteria and procedures for inclusion of drug products on this list.

720.020:   Definitions

The terms used herein shall have the meanings set forth below. Terms defined in M.G.L. c. 112, § 12D and c. 94C, § 1, and not defined herein shall have the meanings set forth therein when used in 105 CMR 720.000, unless the context clearly requires a different interpretation.

Bioequivalent Drug Products  means drug products whose rate and extent of absorption do not show a significant difference when administered at the same molar dose of therapeutic moiety under similar conditions. Some drug products may be equivalent in the extent of their absorption but not in their rate of absorption and yet may be considered therapeutically equivalent because such differences in the rate of absorption are not essential to the attainment of effective body drug concentrations or are considered medically insignificant for the particular drug product studies.

720.020:   continued

Drug products for which bioequivalence is considered essential are those whose bioinequivalence would have therapeutic significance, i.e. use of different brands of the same drug product or different batches of the same drug product would result in therapeutic failure or a hazard to the patient. This is most critical in a drug product that has a narrow therapeutic‑toxicity range which requires careful patient titration and monitoring for safe and effective use.

Commissioner  means the commissioner of public health appointed under M.G.L. c. 17, § 2.

Department  means the Department of Public Health established under M.G.L. c. 17 as an agency within the Executive Department of the Commonwealth of Massachusetts.

Drug Product  means a product which contains an active drug ingredient and is in a dosage form, e.g. tablet, capsule, or solution, generally, but not necessarily in combination with other substances included in the manufacturing process. An active drug ingredient is that portion of a drug product intended to produce a therapeutic effect.

FDA  means the Food and Drug Administration of the United States Department of Health and Human Services.

Generic name  means a non‑proprietary (common) name used to identify a drug product as listed by the United States Adopted Names Council and the United States Pharmacopeia in the USAN/USP Dictionary of Drug Names.

Interchangeable Drug Product  means a product containing a drug in the same amounts of the same active ingredients in the same dosage form as other drug products with the same generic or chemical name.

Pharmaceutically equivalent drug products  means drug products which contain the same active ingredients, and are identical in strength or concentration, dosage form, and route of administration.

Public Health Council  means the Department's governing body established under M.G.L. c. 17, § 3. See also M.G.L. c. 111, § 3.

Therapeutically equivalent drug products  means drug products which are pharmaceutically equivalent; meet applicable standards for strength, quality, purity and identity; are bioequivalent in that:
(a)   they do not present a known or potential bioequivalence problem, and they do meet an acceptable in vitro standard; or
(b)   if they do present such a known or potential problem, they are shown to meet an appropriate bioequivalence standards matching both rate and extent of absorption; are adequately labeled; and are manufactured in compliance with current Good Manufacturing Practice regulations.

720.040:   Commission Review of Relevant Drug Products

In preparing the List of Interchangeable Drug Products and amendments thereto, the Drug Formulary Commission shall determine whether drug products meet the standards set forth in 105 CMR 720.050. In making this determination, the Commission shall assess and evaluate pertinent data, including, but not limited to, the United States Pharmacopeia and its supplements, additional pertinent listings of the FDA, other state formularies, formularies of various hospitals of the commonwealth, and data submitted by manufacturers and other interested persons, including chemical and laboratory listing data and clinical evidence concerning bioequivalence and therapeutic equivalence where available. In reviewing this material, the Commission shall utilize the pharmaceutical and medical expertise of its members.

720.050:   List of Interchangeable Drug Products

The Massachusetts List of Interchangeable Drug Products (MLID) shall consist of:

(1)   drug products which are considered by FDA to be therapeutically equivalent to other pharmaceutically equivalent products listed with the same generic or chemical name according to the most recent edition of "Approved Drug Products with Therapeutic Equivalence Evaluations" and its supplements as published by the United States Department of Health and Human Services:

(2)   drug products specified on a list established by the Department and set forth in 105 CMR 720.200, for which the Commission has determined that the bioequivalence is not essential, or if the Commission has determined that the bioequivalence may be essential, bioequivalence has been established. The list may include the following categories of drug products:
(a)   drug products which hold New Drug Applications (NDAs) or Abbreviated New Drug Applications (ANDAs) approved by the FDA, which FDA does not consider to be therapeutically equivalent to other pharmaceutically equivalent products listed with the same generic or chemical name; and
(b)   drug products exempt from the Food, Drug and Cosmetic Act of 1962, and included in the Drug Efficacy Study Implementation (DESI) done by the National Academy of Sciences/National Research Council; and
(c)   frequently prescribed drug products which were manufactured prior to 1938 and meet the FDA Good Manufacturing Practices Requirements; and
(d)   frequently prescribed over‑the‑counter drug products which contain the same amounts of active ingredients, in the same dosage forms, as other drug products with the same general or chemical name.

720.060:   Drug Products Excluded

The following categories of drug products are excluded from the list of interchangeable drug products:
(a)   drug products for which the Commonwealth has determined that bioequivalence may be essential, but for which bioequivalence has not been established; and
(b)   drug products which are the subject matter of patent rights issued by the U.S. Patent Office, for which provision by other than the patent‑holder would violate the patent; and
(c)   drug products available from only one manufacturer at one price.

720.070:   Amendments to the Massachusetts List of Interchangeable Drugs

(1)   Drug products which meet the criteria specified in 105 CMR 720.050(1) shall be deemed interchangeable and added to the Massachusetts List of Drugs upon publication by the United States Department of Health and Human Services of the most recent edition of "Approved Drug Products with Therapeutic Equivalence Evaluations" and its supplements.

(2)   Drug products which meet criteria specified in 105 CMR 720.050(2) shall be deemed interchangeable and added to the Massachusetts List of Interchangeable Drugs in accordance with procedures set forth in 105 CMR 720.080.

720.080:   Procedures for Amending the Massachusetts List of Interchangeable Drugs

The Department, working with the Commission, shall review at least one a year and revise as necessary the list of interchangeable drug products adopted pursuant to 105 CMR 720.050(2), and shall have the authority to review and revise the list of interchangeable drug products adopted pursuant to 105 CMR 720.050(1) as necessary. The revisions to 105 CMR 720.050(1) shall be specified on an exception list established by the Department and set forth in 105 CMR 720.200. The revisions will add and delete drug products, based on current information concerning therapeutic efficacy and interchangeability of drug products.

720.081:   Petition to Amend List of Interchangeable Drug Products

Any person who desires a drug product or products to be added to or deleted from the List of Interchangeable Drug Products, shall file a written petition with the Department to amend the List, pursuant to M.G.L. c. 30A, § 4. Each petition shall be in such form as the Department may require and shall be submitted to the Drug Formulary Commission.

720.082:   Commission Review of Petition

Upon receipt of a petition, the Department shall submit the petition and the supporting information to the Commission for review. The Commission shall make a preliminary determination whether the List of Interchangeable Drug Products should be amended as proposed.

720.083:   Notice of Public Comment Period

Upon completion of the review of all relevant information, including petitions, by the Commission, the Department shall propose amendments to the List of Interchangeable Drug Products by issuing a Notice of Public Comment Period pursuant to M.G.L. c. 30A, §§ 2 and 3.  The Department shall mail a Notice of Public Comment Period to each person who filed a petition during the period ending 30 days before the Notice of Public Comment Period is issued. In addition, the Department shall mail a Notice of the Public Comment Period to each person who has filed a written request therefore with the Department during December of the previous year pursuant to M.G.L. c. 30A, § 2.

720.084:   Commission Recommendation of Amendments to Department

Following the comment period Department staff shall review all evidence and commentary concerning the proposed amendments, and shall report its recommendation to the Commission. The Commission shall consider the staff recommendations, make such revisions as it deems appropriate, and shall recommend Amendments to the List of Interchangeable Drug Products for adoption by the Commissioner and the Public Health Council.

720.090:   Department Adoption of Amendments

The Commissioner and the Public Health Council shall consider the recommendations of the Drug Formulary Commission, and shall adopt Amendments to the List of Interchangeable Drug Products.

720.100:   Severability

The provisions of 105 CMR 720.000 are severable. If any provision shall be declared invalid by any court, such provision shall be null and void and such determination shall not affect or impair any of the remaining provisions.

REGULATORY AUTHORITY

105 CMR 720.000:   M.G.L. c. 17, § 13; c. 112, § 12D.

720.200:   Appendix A

MASSACHUSETTS
LIST OF
INTERCHANGEABLE DRUGS

Department of Public Health regulation 105 CMR 720.050 describes the Massachusetts List of Interchangeable Drugs.

105 CMR 720.050(a) calls for the automatic adoption of all "A" rated drug products listed in the "Approved Drug Products with Therapeutic Equivalence Evaluations" and its supplements as published by the U.S. Food and Drug Administration (FDA), Department of Health and Human Services. This publication is commonly referred to as the "Orange Book". It is reprinted by the U.S. Pharmacopeial Convention Inc. (USP) as Volume III of the USP DI.

105 CMR 720.050(b) allows for the establishment of the Massachusetts Additional List of Interchangeable Drugs (Additional List), and provides the criteria upon which these drug products are approved.

All prescriptions written by generic name can be interchanged if the drug is multi-source. To determine if a prescription written for a brand name drug product is interchangeable in Massachusetts:

1.   Look up the drug product by the brand name in the index or by generic name in the "Approved Drug Products with Therapeutic Equivalence Evaluations" ("Orange Book"). The drug products are arranged alphabetically.

2.   Compare the dosage form and strength of the drug product prescribed with the dosage form and strength of the same drug product in the "Orange Book".

3.   If the same drug product, dosage form and strength has been assigned an "A" rating by FDA and is not listed on the Exception List contained within 105 CMR 720.050, the drug product is interchangeable.

4.   If the drug product is not listed in the "Orange Book", refer to 105 CMR 720.050(b), the Massachusetts Additional List of Interchangeable Drugs (Additional List).

5.   Look up the drug product by the generic name in the Additional List. The drug products are arranged alphabetically.

6.   Compare the dosage form and strength of the drug product prescribed with the dosage form and strength of the same drug product listed on the Additional List.

7.   If the same drug product, dosage form and strength are listed, the drug product is interchangeable.

Copies of the "Approved Drug Products with Therapeutic Equivalence Evaluations" and its supplements ("Orange Book") are available from the:

U.S. Food and Drug Administration	
Department of Health and Human Services	
Government Printing Office
Washington, D.C. 20402-9371
OPC 6768
(202) 783-3238
and www.fda.gov/cder/drug

720.200:   continued

Copies of the USP DI (third volume of USP DI is the "Orange Book") are available from:

The United States Pharmacopeial Convention, Inc.,
12601 Twinbrook Parkway
Rockville, MD 20852
(301) 881-0666

Copies of the Massachusetts Additional List of Interchangeable Drug Products (document number 105 CMR 720.000) are available from:

The State House Bookstore
Room 116
Boston, MA  02133
(617) 727-2834
and www.magnet.state.ma.us/dph/dcp/Drug Formulary/Drug Interchange

720.200:   continued

	TABLE OF CONTENTS

Foreword

Introduction

Drug Product Problem Reporting Instructions

Exception List

Format of the Additional List

NDA, ANDA, Applicant (name) Changes

Abbreviations

Massachusetts Additional List of Interchangeable Drugs
(Alphabetical list of Official (Generic) Drug Names)

Partial Proprietary Brand Cross-reference

	FOREWORD

The Massachusetts List of Interchangeable Drugs, is prepared by the Drug Formulary Commission (DFC) and the Department of Public Health. The DFC is comprised of nine men and women appointed by the Governor for the express purpose of developing a list of those drug products that are safely interchangeable -- that is, equivalent to each other in all significant respects. The DFC was established by M.G.L. c. 17, § 13. This law was enacted with the intent of saving money for consumers of prescription drugs, since drug products that are marketed under trademark or proprietary names are often available in the generic forms from competing manufacturers at substantially lower prices. M.G.L. c. 112, § 12D mandates prescription forms that allow practitioners to prescribe interchangeable drug products by simply signing the signature line. If a practitioner determines that a brand name drug product should be dispensed, he/she must sign the signature line and write the words "no substitution" in his/her own handwriting in the space provided below the signature line.

The regulations call for the automatic adoption of "A" rated drug products listed in the "Approved Drug Products with Therapeutic Equivalence Evaluations" and its supplements (commonly referred to as the "Orange Book") as published by the U.S. Food and Drug Administration, Department of Health and Human Services, plus a list of additional drug products, the Massachusetts Additional List of Interchangeable Drugs ("Additional List"), individually reviewed and approved by the DFC and the Department. The regulations provide the criteria upon which the drug products listed on the Additional List are approved for interchange. The regulations also provide the DFC and the Department with the authority to review any "A" rated drug product listed in the "Orange Book" or drug product approved for interchange on the Additional List and delete it from the list of interchangeable drug products if deemed appropriate. Drug products assigned an "A" rating by FDA which are deleted from the Massachusetts List are placed on the Exception List. Drug products listed on the Additional List which are subsequently deleted are removed from the Additional List.

Of the many factors considered by the Commission in determining which drugs to include on the List, equivalent safety and effectiveness are paramount. The Commission reviews evidence on bioequivalence and pharmaceutical equivalence and includes on the List only those drug products determined to be fully interchangeable and whose manufacturers are approved by the U.S. Food and Drug Administration. Practitioners may prescribe any drug that appears on the List with confidence that it is as safe and effective as its brand name counterpart.

The efforts of the Commission in the assessment and evaluation of data and the preparation of the List are to be commended. The Department presents the Massachusetts List of Interchangeable Drugs with pride and with confidence that the List will greatly benefit consumers throughout the Commonwealth.

720.220:   continued

	INTRODUCTION

INTERCHANGEABLE (GENERIC) DRUG LAW

In 1976 the Massachusetts Legislature passed an Act Further Regulating the Establishment of a Formulary of Interchangeable Drug Products (St. 1976, c. 470, § 13), commonly known as the Generic Drug Law. This law, enacted to promote and regulate the use of generic drugs, created the Drug Formulary Commission to develop a list of interchangeable drug products and also required the use of a standard prescription form to encourage practitioners to prescribe generic drugs.

PRESCRIPTION FORM

M.G.L. c. 112, § 12D mandates prescription forms with one signature line. If the prescriber signs the prescription form and writes the words "no substitution" in his/her own handwriting in the space provided below the signature line, the pharmacist must fill the prescription exactly as indicated, with no interchange permitted. However, if the prescriber signs the prescription and does not write "no substitution" under his/her signature, the pharmacist is legally required to dispense a less expensive, equivalent interchangeable drug product listed in the Massachusetts List of Interchangeable Drugs if one is reasonably available.

MASSACHUSETTS LIST OF INTERCHANGEABLE DRUGS

The Massachusetts List of Interchangeable Drugs (MLID) consists of the "A" rated drug products listed in the "Approved Drug Products with Therapeutic Equivalence Evaluations" and its supplements as published by the U.S. Food and Drug Administration, Department of Health and Human Services ("Orange Book") and the Massachusetts Additional List of Interchangeable Drugs (Additional List). The Additional List is developed by the Drug Formulary Commission. The Commission determines drug products to be interchangeable only when they meet certain criteria:
(a)   the drug product is available from more than one source, with the same active ingredient in the same dosage form and strength;
(b)   its manufacturer is approved by the U.S. Food and Drug Administration (FDA); and
(c)   when essential to therapeutic outcome, the manufacturer of the drug has documented clinical evidence of bioequivalence.

The Commission judges that all the drugs included on the MLID meet these standards and are bioequivalent, if essential, based on assessment and evaluation of the U.S. Pharmacopeia and its supplements, other state and hospital formularies, listings of the U.S. Department of Health and Human Services of the FDA, and on the expertise of its members.

The List does not include:
(a)   drugs that are protected by patent rights or available from only one source;
(b)   many controlled-release and enteric coated drug products since they may not consistently deliver the same quantities of their active ingredients;
(c)   those drugs for which the Commission had any significant doubt about safe interchange between manufacturers; and
(d)   any drug for which bioequivalence is considered essential but for which bioequivalence has not been demonstrated or an appropriate standard for bioequivalence has not been established.

Bioequivalence is determined to be necessary for a particular drug when bioinequivalence might result in therapeutic failure or hazard to the patient. Bioequivalent drug products do not show a significant difference in the rate and extent of absorption when administered at the same dosage under similar conditions. Drugs that are equivalent in the extent to which they are absorbed into a patient's body that differ in the rate of absorption may be therapeutically equivalent -- having the same medical effect -- either because the rate of absorption is not essential to the attainment of effective body concentrations of the drug, or because the difference in  the   rate  is  otherwise considered   medically  insignificant.  Bioequivalence  is  a  primary

720.220:   continued

consideration for those drug products with a narrow therapeutic/toxic dosage range (when variation in the rate or extent of absorption could have a critical effect) where careful determination of the correct dosage and monitoring of the patient is essential to safe and effective use. To determine for which drugs bioequivalence is essential, the Commission relies on expert medical testimony, studies done by the pharmaceutical industry, the knowledge and expertise of the individual members of the Commission, and advice from the FDA.

All drug products manufactured by FDA approved firms are considered safe and effective for their intended use, even if the product has not been included in the MLID. A practitioner may begin a patient's therapy with a drug product from any manufacturer who has been approved by the FDA, even though interchange of the drug once the dosage has been calculated for the individual is not advised.

Several generic drug products are manufactured under the same new drug application (NDA) as the brand name drug products.  According to section 1.6 of the Orange Book, drug products with the same NDA are therapeutically equivalent.  Massachusetts regulations allow the interchange of these products.  Distributors or repackagers of drug products manufactured under the same NDA as the brand name product are not identified in the Orange Book.  Pharmacists who may not be able to determine if drug products are interchangeable should contact the manufacturers, distributors or repackagers.  In addition the Department maintains an unofficial list of these products.

Information relative to the Interchangeable (Generic) Drug Law may be obtained from the Department of Public Health, Division of Food and Drugs, 305 South Street, Jamaica Plain, MA  02130, telephone number (617) 727-2670, and from the Boards of Registration in Medicine, Dentistry and Pharmacy.

	DRUG PRODUCT PROBLEM REPORTING INSTRUCTIONS

Since 1971 the United States Pharmacopeia (USP), in cooperation with various professional associations and the Food and Drug Administration (FDA), has operated the Drug Product Problem Reporting Program. This program can be utilized by pharmacists, physicians, or consumers to report any product problems encountered when using drugs interchanged under the Massachusetts generic drug law. The program is product oriented, and patient identification not requested. Should you prefer to remain anonymous, so indicate to the USP and your name will be withheld from the manufacturer and the FDA. Your participation in reporting problems will help to ensure that the drug products prescribed and dispensed in Massachusetts are of continued high quality.

Reports should be sent to The United States Pharmacopeial Convention, Inc., 12601 Twinbrook Parkway, Rockville, MD 20852, (301) 881-0666. The USP is an impartial, non-governmental organization concerned with drug standards and quality control. After USP receives a report, copies are forwarded to the FDA and to the manufacturer of the product involved. Either the FDA or the manufacturer may act to investigate or correct problems.

	EXCEPTION LIST

Orange Book "A" rated drug products not approved for interchange.

There are currently no products designated to be listed on the Exception List.

	ADDITIONAL LIST

The Massachusetts Additional List of Interchangeable Drugs (Additional List) has been printed in a format designed to be concise and understandable. Interchangeable drugs are listed alphabetically according to their official (chemical or generic) names, and separate sections in each listing show dosage forms, strengths, FDA approved manufacturers, and categories.

720.220:   continued

DRUG

Drugs are listed in alphabetical order by their generic names and are printed in capital letters. Drug products containing more than one active ingredient (for example, CODEINE PHOSPHATE, GUAIFENESIN) are listed in the conventional order of ingredients.

	Only drug products grouped under single headings are to be interchanged.

DOSAGE FORM

Under the generic names are listed the various multisource dosage forms in which a drug product is available. Abbreviations used for dosage forms and approved manufacturers are found in the front of the Additional List.

	Only identical dosage forms and strengths of identical drugs are to be interchanged.

STRENGTH

The approved strengths of the drug products are listed under the heading "Strength(s)." The "strengths" must be read along with the "dosage forms" since any strength shown is available only for the dosage form directly to its left. Dosage strength is in metric units that are sometimes rounded off from apothecary measures, which may introduce slight variations in the strength of certain products. Single ingredient drug product strengths are separated by commas. Combination drug products have a slash separating the strengths of the individual ingredients. If more than one strength of a single component of a combination drug product is approved, they will be separated by commas. For example, the strength of a tablet of aspirin with codeine phosphate is "325mg / 15mg, 30mg, 60mg" which means that the combination is available with 325 milligrams of aspirin and 15, 30, or 60 milligrams of codeine phosphate. Drug products with three or more components have their active ingredients listed individually in parentheses and have slashes separating the strengths of the individual ingredients.

MANUFACTURERS

Next to the heading "Manufacturers" are all approved manufacturers for the drug product in that group, listed by three letter abbreviations in capital letters. (See list of manufacturer abbreviations in front of the Additional List.) Listed manufacturers have met all legal requirements, including compliance with the FDA Good Manufacturing Practices for the production of the drug product indicated. Approved manufacturers hold current new drug applications (NDAs) or abbreviated new drug applications (ANDAs) when required by law.

	NDA, ANDA APPLICANT (NAME) CHANGES

Because it is not practical to identify in the Massachusetts Additional List of Interchangeable Drugs (Additional List) each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name, these transfers and name changes are identified in this section. In addition, the new manufacturers are listed in parenthesis beside the original manufacturer under the Manufacturers' Abbreviations section of the Additional List. Where only partial approved product lines are transferred between applicants, each approved product involved will appear with the manufacturer name change in the Additional List amendment.

Previously listed name changes have been incorporated into the revised Manufacturers’ Abbreviations section.

	ABBREVIATIONS

The following abbreviations are used in the Massachusetts List of Interchangeable Drugs.

720.200:   continued

	DOSAGE FORMS

aero					aerosol
amp					ampule
cap					capsule
conc					concentrate
e.c. 					enteric-coated
elix					elixir
g					gram
Hbr					hydrobromide
HCl					hydrochloride
HC					hydrocortisone
inhl					inhalation
inhl liquid					inhalation liquid
inhl sol					inhalation solution
inj					injection
irr sol					irrigating solution
I.U. 					international units
liq					liquid
lot					lotion
mcg					microgram
mEq					milliequivalents
mg					milligram
ml					milliliter
oint					ointment
ophth					ophthalmic
oral gran					oral granules for
 reconstitution
oral powder				oral powder for
 reconstitution
oral sol					 oral solution
pow					powder
sol					solution
SR					sustained release
subl tab					sublingual tablet
supp					suppository
susp					suspension
syr					syrup
tab					tablet
top aero					topical aerosol
top swab					topical swab
U					units
vag					vaginal

	MANUFACTURERS' ABBREVIATIONS

3MP			3M Pharmaceutical
AAA 			Alpha Therapeutic
ABB 			Abbott
ABI			Abic
ABL 			Able Laboratories
ACI			ACIC Limited
ACP			Advanced Care Prod.
ADV			Advanced Remedies
AGV			Agvar Chemicals
AKO 			Akorn
AKZ			Akzona Inc.
ALC 			Alcon Labs
ALL 			Allergan Pharmaceuticals
ALI			Alliance Pharmaceutical
ALP			Alpharma
APP			Alphapharm Party
ALT			Altana
ALZ			Alza Corp.
ALR 			Alra Laboratories
AMA			Amaric
AMB 			Ambix Labs
ACC			American Cyanamid Co.
AHP			American Home Products
ARL			American Regent Labs.
AME			Amersham
AMG			Amgen
AMI 			Amide Pharmaceuticals
AMT 			American Therapeutics
ANA			Anabolic
ANB			Anbex
ANC			Angus Chemical
ANE			Anesta
ANG			Angelini
APO			Apothecon
APK	Apothekernes
APP	American Pharmaceutical Partners
  Inc 
ARC	Arcola Labs.
APC 	Arcum Pharmaceuticlal Corp.
ARP	Armenpharm
ARM 	Armour Pharmaceuticals
ASC 	Ascot Hospital Products
ASA	Asta
ASP	Astra Pharmaceuticals LP
ATH	Athena Neurosciences
BAK	Baker Norton
BAN	Banner Pharmacaps
BAP	Barlan Pharmacal
B/I 	Boehringer Ingelheim
B/M	Boehringer Mannheim. Ther. Div
BAR 	Barr Labs
BAS	Basel Pharmaceuticals
BAT 	Bartor
B&L	Bausch & Lomb
BAY 	Bayer Corp
BEA	Beach Prod.
B-D	Becton,Dickinson & Co.
BED	Bedford Laboratories
BEL	Bell
BDP 	Beta Derm Pharmaceuticals
BER	Berlex
BFA	B.F. Asher
BHC 	B.H. Chemicals
BID	Biodevelopment
BIO	Bio Technology General
BIV	Biovail
BLA	Blairex Laboratories
BLO	Block Drug Co.

BLU		Bluline
BRL		Blue Ridge Laboratories
BOC		Bock Pharmacal
BOW		Bowman Pharm.
BMS		Bristol Myers Squibb
BRC		Bracco Diagnostics
BRD		Bradley Pharm.
BRA		Braintree Laboratories
BRI		Bristol-Myers Prod.
BTG		BTG Pharmaceuticals
BVL 		Ben-Venue Labs
BYR		Byron Chemical
C&M		C & M Pharmacal
CAD		Cadema Medical Products
CAG		Calgon Corp.
CDC		Carderm Capital
C-P 		Chesebrough - Ponds
C-W 		Cook - Waite
C/C 		Chase Chemical
CSL		Chase Laboratories
C/P 		Corvit Pharmaceuticals
CAL 		Carlisle
CAM 		Camall
CAR 		Carnick Labs
CTW		CarterWallace
CEN 		Century Pharmaceuticals
CBV		Cetus Ben Venue Therapeutics
CHA 		Chamberlin Parenteral Corp.
CHE 		Chelsea Laboratories
CHM		Chemed Corp.
CVO		Ciba Vision Ophthalmics
CIR		Circa Pharmaceuticals
CJD 		Copanos, J.D.
CLA 		Clay - Park
CLO		Clonmel Healthcare
CMB 		C.M. Bundy
CMC 		Consolidated Midland Corp.
C/T		Controlled Therapeutics
CMP 		Carolina Medical Products
CNC		H.R. Cenci
COL		Colgate Palmolive
COM		Combe
CON		Connaught Laboratories
COO 		Cooper Labs
COP 		Copley Pharmaceutical
CPG		Consolidated Pharmacy Group
CRE		Creighton Products
CUM		Cumberland Swan
CUR		Curatex Pharmaceuticals
CTL 		Central Pharmacal
D&G		Davis & Geck
D/L		DPT Laboratories
D-R 		Del-Ray Laboratories Inc.
DAN 		Danbury Pharmacal
DAR		Darby Group Companies
DEL 		Dell
DEP 		Deproco
DER 		Dermik Laboratories
DES		Deseret Medical
DEY 	Deylabs
DHL	DHL Laboratories
DIA	Dial Corp.
DIS 	Dista
DMD 	Duramed
DMG 	D M Graham Laboratories
DOW	Dow Pharmaceutical
DPT 	Dupont Pharmaceuticals
DPM	Dupont Merck
DUR	Dura Pharmaceuticals
DUN 	Dunhall
DYN	Dynapharm
E/K	Eastman Kodak
EAT	Eaton Medical Corp.
ECR	ECR Pharmaceuticals
ELA	Elan Pharmaceuticals
ELL	Ellis Pharmaceuticals
EMP	EM Pharma
END 	Endo
EON	Eon Laboratories
ENQ	Enquay Pharm
ENZ	Enzon
ESR 	Elkins-Sinn/AH Robins
ERS	Ersana
ESI	ESI Lederle Generics
ESP	ESI Pharmacal
ETH	Ethicon Inc.
ETX	Ethex
ETK	Ethitek Pharmaceuticals
EVY	Everylife
EZC	E Z EM Co.
FAU	Faulding Pharm. Co.
FER 	Ferndale
FRT	Ferrante
FRR	Ferring Labs
FIS 	Fisons
FLE	Fleming & Co.
FOR 	Forest
FOU	Fougera
FOY 	Foy
FRE	Fresenius
G&W 	G & W
GAL	Galderma
GEI	Geigy
GEC	Gencon
GED	Genderm
GET	Genentech
GEP	Genpharm
GEV 	Geneva
GES	Gensia Sicor Pharmaceuticals Inc
GEZ	Genzyme
GIL 	Gilbert Laboratories
GLD	Glades
GLW	GlaxoWellcome
GLE 	Glenwood
GLO	Global Pharm.
G/P	Golden Pharms.
GOL	Goldine
GRE	Greenstone
GRI	Griffen,KW
G/L	Gruppo Lepetit

GUA	Guardian
GYM	GYMA Laboratories
GYN	Gynopharm
H-R 	Holland-Rantos
HAL 	Halsey Labs
HAM	Hamilton Pharmaceuticals
HAN	Hnford GC
HEA 	Heather
HEN 	Heran Pharmaceutical
HEX	Hexcel Chemical Products
HER	Hermal Pharmaceutical
HIC	Hickam
H/D	Hill Dermaceuticals
HIR	Hirsch Industries
HIT	Hi Tech Pharma
HTP	High Technology Pharmacal
HLC 	Halocarbon
HCC	Hoechst Celanese Corp.
HMR	Hoechst Marion Roussell
HOE 	Hoechst-Rousel
HOR	Horus Therapeutics
HOY 	Hoyt
HUD 	Hudson Pharmaceuticals
HUN 	Huntington
HYB	Hybritec Inc.
HYG	Hygenics
HYR 	Hyrex
IMM	Immunex
IMP	IMP Inc.
ICN	ICN Pharmaceuticals
IMS 	International Medication
INP 	Interpharm
INV 	Invamed, Inc.
INW 	Inwood Labs
ICC	Interchem Corp.
ILC	International Latex Corp.
ING	Ingram Pharmaceutical
INH	Inhalon
IOL	Iolab
IOM	Iomed
IPR	IPR Pharm
IVA	IVAX
J&J 	Johnson & Johnson
JAC 	Jacobus
JAN	Janssen Pharmaceuticals
JER 	Jerome Stevens Labs
JRW	Johnson RW
JON	Jones Pharma Inc
KAL	Kalapharm
KBP	Kabi Pharmacia
KEE 	Keene
KED	Kendall
KEN 	Kenwood
KIN	King Pharmaceuticals
KIR	Kirkman Sales
KNO 	Knoll
KPI 	Key Pharmaceuticals
KVP	KV Pharmaceutical Co.
L/F	Labs Fournier
L/A 		Laboratories Atral
LAF		Lafayette Pharms
LAN 		Lannett
LED 		Lederle
LEI		Leiras
LEK		Lek Ljubliana
LEM 		Lemmon
LEO		Leo Pharms
LIF		Life Labs
LIL		Lilly
LIP		Liposome
LIQ		Liquipharm
LNK 		LNK International
LOC 		Loch Pharmaceuticals
LOR		Lorex 
LOT		Lotus Biochemical
LPI		LPI Holding
LUI 		Luitpold
LUS		Lek USA Inc.
LYN 		LYNE Laboratories
M/P 		Mallinckrodt Pharmaceutical.
MAY		Mayrand
MAT		Matrix Labs
MCG 		Mcgaw
MCN 		McNeil Consumer Products
MDP 		MD Pharmaceuticals
MEA 		Mead Johnson
MJN		Mead Johnson Nutritionals
M/R		Medco Research
MVA		Medeva
MEP 		Medics Pharmaceuticals
MPI		Medi Physics, Inc.
MAG		Mepha AG
MER		Mericon
MET		Metronic
MGI		MGI Pharma
MID		Midway Medical
MIK		Mikart Laboratories
MIS 		Mission Pharmacol
MJP 		MJ Pharmaceuticals
MKL 		Moore Kirk Labs
MLI 		Marchar Laboratories
MLP 		Miller Pharmacal
MLX 		Milex
MMD		Marion Merrell Dow
MOR		Morton Grove
MCK		Merck & Co.
MSM 		Marsam
MSL		Marshall Pharmacal
MTC		Martec
MOV		Mova
MUR		Muro
MUT		Mutual Pharmaceuticals
MYL 		Mylan Pharmaceuticals
NEP		Nephron Pharmaceuticals Inc
NEU		Neutrogena
NOR		Norbrook Laboratories
N/W		Norton Waterford
N/N 		Novo Nordisk 
NEW		Newtron Pharmaceuticals
NHN		Norton HN

NOV 		Novocol
NVP 		Novopharm Ltd.
NUM		Numark
NYC		Nycomed
NYL		Nylos Trading
ORI		Organon, Inc.
OCL		Oclassen
OHM		OHM Laboratories
OMD		Ohmeda Pharmaceutical
OSA		On Site Azla
ODC		Ormont Drug & Chemical
OPC		Ortho Pharmaceuticals
OPT		Optopic Laboratories Corp.
ORG		Organics
OAP		Otsuka America Pharmaceutical
PAK		Pal-Pak
PAL		Palisades
P/D 		Parke Davis
P/I		Plantex/Ikpharm
P/K 		Purepac-Kalipharma
P/P 		Parmed Pharmaceuticals
PAC 		Paco Research
PAD	 	Paddock Labs
PHD		Pharmaderm
PAN 		Panray
PAR 		Par
PNL		Parnell
PER		Perrigo
PCE 		Pharmachemie
PHC		Pharmics
PHK		Pharmakinetics Labs
PHM		Pharmeral
PHO		Phoenix Labs
PHS		Pharma Serve
PHT		Pharmaton
PFF 		Pfeiffer
PFI 		Pfizer
P/U		Pharmacia & Upjohn
P/A		Pharmaceutical Association
PIO 		Pioneer Pharmaceutical Inc.
PPI 		Physicians Products Inc.
PSA		Pharmaceutical Specialist Assoc
POH		Pohl Boskamp
POL		Polymedia
PGP		Prographarm
PRD		Professional Disposables
PRO		Proter Laboratory
PRI 		Private Formulations
P&G		Proctor & Gamble
PRV 		Pharmavite
PTK 		Pharma-Tek
PUF		Purdue Frederick
PUR		Purepac
QUA 		Quantum Pharmics Ltd.
QLT		QLT PhototherapeuticsInc.
RAN		Ranbaxy Pharmaceuticals
R/C		Reckitt & Colman
R&C 		Reed & Carnrick
R/I		Research Industries
RXP		Rexar Pharmacal
RAC		Rachelle Labs
REN		Ren-Pharm Internatl. Ltd.
RHP		Rhone - Poulenc
RPR		Rhone-Poulenc Rorer
RAH 		Robins, A.H.
REX 		Rexall/Sundown
RIC 		Richlyn Labs
ROC		Roche Labs.
RPF		Roerig/Pfizer
ROA		Roaco
RBP		Roberts Pharmaceutical
ROR 		Rorer
ROS 		Ross Labs
ROX 		Roxane Labs
ROY 		Royce Laboratories
RPC		Rosemont Pharmaceutical Corp.
RUG 		Rugby Labs
S-M		Spencer-Mead
S/W		Sanofi Winthrop
S/L		Schmid Laboratories
SAK		Sankyo
SAV		Savage Labs/Altana
SAN		Sandoz
SCE		Scherer, R.P.
SPI		Schein Pharmaceutical, Inc.
SCH		Schering Corporation
S/P		Schering/Plough
SWZ		Schwarz Pharma
SZG		SchwarzGMBH
SCI		ScinoPharm International
SCS		SCS Pharmaceuticals
SEA		Searle
SER		Serono Laboratories
SEQ		Sequus Pharmaceuticals
SHM		Sherwood Medical
SHI		Shionogi USA
SID		Sidmak Laboratories
SIG		Sigma Tau
SIX		Silarx
SKB		Smith, Kline Beecham
SBH		Sola Barnes Hind
SOL		Solopak Laboratories
SLV		Solvay
SOM		Somerset
SBM		Sorin Biomedics
SDP		Sperti Drug Products
STI		Steifel
STL		Stanlabs Pharmaceutical Co.
STR		Star Pharmaceuticals
STS		Steris Laboratories
STZ		Storz Ophthalmics
SUP		Superpharm
SPP		Suppositoria
SUR		Survival Technology
SYN		Syntex
SYO		Syosset Labs
TAB		Tablicaps
TAG		Tag Pharmaceuticals
TAK		Takeda
TAP		Tap Holdings

TAR 		Taro Pharmaceutical
TAY		Taylor Pharmaceuticals
TEC		Technilab
THE		Theratech
THK		Therakos
THA 		Thames Phamacol Co. Inc.
TIC		Tican Pharmaceuticals
TOP		Topiderm
T/L		Torch Laboratories
TOR		Torigian Lab
UDL		UDL Laboratories
UMD		Unimed
UPJ 		Upjohn
USL 		Upsher-Smith Labs
VAL 		Vale Chemical
VAN 		Vangard
VES 		Vestal
VIC		Vicks Pharmacy Products
VIN		Vintage
VIR		Viratek
VIS		Vistakon, Inc.
VIV		Vivan Pharmacal
W-A 	Wyeth Ayerst
W-C 	Warner-Chilcott
WAW	Warner Wellcome
WRR	Warrick Pharm
WEP	WE Pharmaceuticals
WEN	Wendt Laboratories
WPP	West Point Pharma
WES	Westwood Squibb Pharmaceuticals
W-W 	West-Ward
W/L 	Wharton Labs
WBY	Whitby
WWT	Whiteworth Towne
WAL 	Wallace Labs
WAR 	Warner-Lambert
WAT 	Watson Laboratories
WOC	Wockhardt
XTT	Xttrium Laboratories
YAM	Yamanouchi
YOS 	Yoshitomi Laboratories
ZCA	Zeneca
ZGP	Zenith Goldline Pharmaceuticals

MASSACHUSETTS ADDITIONAL LIST OF INTERCHANGEABLE DRUGS

AMINOPHYLLINE, EPHEDRINE Hcl
Dosage form(s):	TABLETS	Strength(s): 130mg/25mg
Manufacturers:	STL
Category:		OTC

AMYL NITRITE
Dosage form(s):	INHALATION	Strength(s): 0.3ml
Manufacturers:	GLW, CMC
Category:		PRE-38

ASPIRIN W/ CODEINE PHOSPHATE
Dosage form(s):	TABLET	Strength(s): 325mg/15mg, 30mg, 60mg
Manufacturers:	BAR,  GLW, CHE, GEV, HAL, P/D, ZGP
Category:		PRE-38

ATROPINE SULFATE
Dosage form(s):	OPHTHALMIC SOLUTION	Strength(s): 0.5%, 1%, 2%
OPHTHALMIC OINTMENT	0.5%, 1%
Manufacturers:	ALC, ALL, ESR, FOU, INV, MUR,  B&L, STS, SUR
Category:		PRE-38

ATROPINE SULFATE COMPOUND (ATROPINE SULFATE, SCOPOLAMINE HBr, HYOSCYAMINE SULFATE, PHENOBARBITAL)
Dosage form(s):	TABLET	Strength(s): 0.0194mg/0.0065mg/
0		1037mg/16.2mg
Manufacturers:	ALL, CHE, M/P, MAY,  TAY, RAH, WES
Category:		DESI

BENZOCAINE, ANTIPYRINE
Dosage form(s):	OTIC SOLUTION	Strength(s): 1.4%, 5.4%
Manufacturers:	AMB, W-A, CLA, RPC, S-M, THA
Category:		PRE-38

BENZOYL PEROXIDE
Dosage form(s):	GEL	Strength(s): 2.5%, 5%, 10%
Manufacturers:	BMS, CLA, GAL, STI, SYO, VIC, WES
Category:		OTC

BENZTHIAZIDE
Dosage form(s):	TABLET	Strength(s): 50mg
Manufacturers:	GEV, PFI, RAH, 
Category:		B

BROMPHENIRAMINE MALEATE,  DEXTROMETHORPHAN HBr,  PSEUDOEPHEDRINE HCl
Dosage form(s):	SYRUP	Strength(s): 2mg/10mg/30mg/5ml
Manufacturers:	RAH,  RPC
Category:		OTC

BROMPHENIRAMINE MALEATE, PHENYLPROPANOLAMINE HCl, PHENYLEPHRINE, GUAIFENESIN COMBINATION
Dosage form(s):	SYRUP	Strength(s): 4mg/5mg/5mg/100mg/5ml
Manufacturers:	HAL, LIF, RAH, RPC, 
Category:		OTC

CAFFEINE AND SODIUM BENZOATE
Dosage form(s):	INJECTION	Strength(s): 250mg/ml
Manufacturers:	TAY
Category:		PRE-38

CALCIUM GLUCONATE
Dosage form(s):	INJECTION	Strength(s): 10%
Manufacturers:	ARL, APC, APP, CMC, CEN,  BAY,  ESR, GEN, HYR, KIR, LAN,
LIL, M/P, P/D, RIC, STL, P/U ,
Category:		PRE-38

CARBINOXAMINE MALEATE,  PSEUDOEPHEDRINE HCl,  DEXTROMETHORPHAN HBr
Dosage form(s):	DROPS	Strength(s): 2mg/25mg/4mg/ml
SYRUP	4mg/60mg/15mg/5ml
Manufacturers:	ALP, ROS
Category:		PRE-38

CHLORAL HYDRATE
Dosage form(s):	CAPSULE	Strength(s): 500mg
SYRUP	250mg/5ml,  500mg/5ml
Manufacturers:	BMS, C/C, ALP, PHC, PUR, ROX, SCE, , ZEN
Category:		PRE-38

CHLORDIAZEPOXIDE W/ CLIDINIUM BROMIDE
Dosage form(s):	CAPSULE	Strength(s): 5mg/2.5mg
Manufacturers:	BAR, CHE, EON, GEV, HAL,  ROC, LEM, PAR, QUA, ZGP
Category:		DESI

CHLOROTHIAZIDE W/ RESERPINE
Dosage form(s):	TABLET	Strength(s): 250mg/0.125mg, 500mg/0.125mg
Manufacturers:	MCK, MYL, 
Category:		B

CHLORPHENIRAMINE MALEATE
Dosage form(s):	TABLET	Strength(s): 4mg, 8mg, 12mg
SYRUP	2mg/5ml
Manufacturers:	LAN, SCH
Category:		OTC

CHOLINE MAGNESIUM TRISALICYLATE (CHOLINE SALICYLATE, MAGNESIUM SALICYLATE)
Dosage form(s):	TABLET	Strength(s): 500mg (=293mg/362mg), 
750mg (=440mg/544mg), 
1000mg (=587mg/725mg)
Manufacturers:	PUF, SID
Category:		PRE-38

CODEINE PHOSPHATE
Dosage form(s):	INJECTION	Strength(s): 15mg, 30mg, 60mg/ml
Manufacturers:	ESR, KNO, STL, W-A
Category:		PRE-38

CODEINE PHOSPHATE /GUAIFENESIN LIQUID
Dosage form(s):	LIQUID	Strength(s): 10mg/100mg/5ml
Manufacturers:	RAH, HAL
Category:		PRE-38

CYANOCOBALAMIN
Dosage form(s):	TABLET	Strength(s): 10mcg, 25mcg, 
CAPSULE	50mcg, 100mcg, 250mcg
Manufacturers:	APP, BER, BMS, STS, DEL, ESR, INV, LEM, LIL, MMD, MCK, ALP,  ORI, P/D,
SAV, SOL,  P/U, W-A
Category:		OTC

CYCLANDELATE
Dosage form(s):	CAPSULE	Strength(s): 200mg/400mg
Manufacturers:	CHE, GEV, DAN, FOR, INW,  W-A, LAN, LEM, MDP, PAR, PIO, ZGP
Category:		DESI

DEXAMETHASONE
Dosage form(s):	TABLET	Strength(s):0.25mg, 0.5mg, 0.75mg, 1.5mg, 4mg
Manufacturers:	GEV, DAN,  MCK, MYL, ORI, PAR, PRI, RIC,  SLV, ROX, , USL
Category:		B

DIETHYLPROPION HCl
Dosage form(s):	TABLET	Strength(s): 25mg
SUSTAINED RELEASE TABLET	75mg 
Manufacturers:	CAM, , LEM, MMD, MDP,  3MP
Category:		B

DIETHYLSTILBESTROL
Dosage form(s):	TABLET	Strength(s): 0.1mg, 0.5mg, 1.5mg
VAGINAL SUPPOSITORIES
Manufacturers:	BMS, LIL
Category:		B

DIGOXIN
Dosage form(s):	TABLET	Strength(s): 0.125mg, 0.25mg, 0.5 mg
Manufacturers:	GLW, AMI
Category:		PRE-38

DIGOXIN
Dosage form(s):	INJECTION	Strength(s): 0.25mg/ml, 0.5mg/2ml
Manufacturers:	GLW,  ESR, EON, W-A
Category:		PRE-38

DIMENHYDRINATE
Dosage form(s):	TABLET	Strength(s): 50mg
Manufacturers:	ANA, STS, CHE, GEV,  ESR, LEM, SEA, , W-A
Category:		OTC

DIPHENHYDRAMINE HCl
Dosage form(s):	CAPSULE	Strength(s): 25mg, 50mg
ELIXIR	12.5mg/5ml
Manufacturers:	HAL, ICN, P/D
Category:		OTC

DISULFIRAM
Dosage form(s):	TABLET	Strength(s): 250mg, 500mg
Manufacturers:	W-A, DAN
Category:		B

EPINEPHRINE HCl
Dosage form(s):	INJECTION	Strength(s): 0.01%, 0.1%
OPHTHALMIC SOLUTION	0.1%, 0.25%, 0.5%, 1%, 2%
Manufacturers:	ABB, ALC, ALL,  ARL, ESR,IMS, INV, LAN, P/D, W-A  
Category:		PRE-38

ESTROGENS, ESTERIFIED
Dosage form(s):	TABLET	Strength(s): 0.3mg, 0.625mg, 1.25mg, 2.5mg
Manufacturers:	BMS, PRI,  SLV, SKB, SYN
Category:		B

ETHAVERINE HCl
Dosage form(s):	CAPSULE	Strength(s): 100mg
TABLET
Manufacturers:	BFA, KEN, LEM, MEP
Category:		PRE-38

ETHINYL ESTRADIOL
Dosage form(s):	TABLET	Strength(s): 0.02mg, 0.05mg
Manufacturers:	ORI, SCH,  P/U
Category:		B

FLUOXYMESTERONE
Dosage form(s):	TABLET	Strength(s): 2mg, 5mg, 10mg
Manufacturers:	BMS, RPC, P/U
Category:		B

GLYBURIDE
Dosage form(s):	TABLET	Strength(s): 1.25mg, 2.5mg, 5mg
Manufacturers:	HOE, P/U
Category:		B

HYDRALAZINE HCl, HYDROCHLOROTHIAZIDE, RESERPINE
Dosage form(s):	TABLET	Strength(s): 25mg/15mg/0.1mg
Manufacturers:	DAN, GEI, LEM
Category:		B

HYDROCHLOROTHIAZIDE W/ RESERPINE
Dosage form(s):	TABLET	Strength(s): 25mg/0.125mg, 50mg/0.125mg, 
25mg/0.1mg, 50mg/0.1mg
Manufacturers:	KNO, CAM, GEI, GEV, DAN, LEM,  MCK, PUR, ZGP
Category:		B

HYDROCODONE BITARTRATE W/ PHENYLPROPANOLAMINE
Dosage form(s):	SYRUP	Strength(s): 5mg/25mg/5ml
Manufacturers:	DPT,  ALP, RPC
Category:		OTHER

HYDROCORTISONE, IODOCHLORHYDROXYQUIN
Dosage form(s):	CREAM	Strength(s): 0.5%, 1% / 3%
OINTMENT
Manufacturers:	AMB,  ALT, CLA, DER,  BAY, DUR, GEI, LEM, ALP, SLV, THA, 
Category:		DESI

HYDROFLUMETHIAZIDE, RESERPINE
Dosage form(s):	TABLET	Strength(s): 25mg, 50mg/0.125mg
Manufacturers:	APO,  RPC, ZGP
Category:		B

HYDROQUINONE 4% CREAM 
Dosage form(s):	TOPICAL CREAM	Strength(s): 4%
Manufacturers:	ICN, ETX
Category:		PRE-62

HYDROQUINONE CREAM 4%   
Dosage form(s):	CREAM	Strength(s): 4%
Manufacturers:	ICN; GLD
Category:	PRE-1962

HYDROQUINONE 4% CREAM with SUNCREENS 
Dosage form(s):	TOPICAL CREAM	Strength(s): 4%
Manufacturers:	ICN, ETX
Category:		PRE-62

HYDROQUINONE CREAM 4% with SUNCREEN
Dosage form(s):	CREAM	Strength(s): 4%
Manufacturers:	ICN; GLD
Category:	PRE-1962

HYDROQUINONE TOPICAL SOLUTION 
Dosage form(s):	TOPICAL SOLUTION	Strength(s): 3%
Manufacturers:	NEU, GLD
Category:		PRE-38

NON-TEXT PAGE

MASSACHUSETTS ADDITIONAL LIST OF INTERCHANGEABLE DRUGS

ISOSORBIDE DINITRATE
Dosage form(s):	SUSTAINED RELEASE CAPSULE	Strength(s): 40mg
Manufacturers:	ASC, GEV, FOR, W-A, SUP
Category:		B

ISOXSUPRINE HCl
Dosage form(s):	TABLET	Strength(s): 10mg, 20mg
Manufacturers:	GEV, MEA
Category:		PRE-38

L-HYOSCYAMINE SULFATE
Dosage form(s):	TABLET	Strength(s): 0.125mg
Manufacturers:	BFA, GLW, SWZ
Category:	PRE-38

LEVODOPA
 Dosage form(s):	TABLET	Strength(s): 250mg, 500mg
CAPSULE	100, 250, 500mg
Manufacturers:	ROC,  P&G
Category:		B

MAGNESIUM SALICYLATE
Dosage form(s):	TABLET	Strength(s): 600mg
Manufacturers:	BFA, END, RBP, MLP, , 
Category:		OTHER

MAGNESIUM SULFATE
Dosage form(s):	INJECTION	Strength(s): 10%, 12.5%, 50%
Manufacturers:	ABB, APP, ARL, CMC, ESR, IMS, LIL
Category:		PRE-38

MAZINDOL
Dosage form(s):	TABLET	Strength(s): 1mg
Manufacturers:	SAN, W-A
Category:		B

MEPHOBARBITAL
Dosage form(s):	TABLET	Strength(s): 32mg, 100mg, 200mg
Manufacturers:	BOW, ICN, S/W
Category:		PRE-38

METHENAMINE MANDELATE
Dosage form(s):	SUSPENSION	Strength(s): 0.25, 0.5g/5ml
TABLET	0.25g, 0.5g, 1g
ENTERIC COATED TABLET	0.25g, 0.5g, 1g
Manufacturers:	GEV,  HEA,  ALP, P/D, RIC,  SLV, TAB
Category:		PRE-38

METHENAMINE COMBINATION (METHENAMINE, PHENYLSALICYLATE, ATROPINE SULFATE, HYOSCYAMINE, BENZOIC ACID, METHYLENE BLUE)
Dosage form(s):	TABLET	Strength(s): 40.8mg/18mg/0.03mg/
0.03mg/4.5mg/5.4mg
Manufacturers:	CHE, LEM, , S-M, STR
Category:		DESI

METHYLENE BLUE
Dosage form(s):	INJECTION	Strength(s): 1%
TABLET
Manufacturers:	ARL, CMC, ESR, TAY,
Category:		PRE-38

METHYLTESTOSTERONE
Dosage form(s):	CAPSULE	Strength(s): 10mg
SUBL. TABLET	10mg, 25mg
Manufacturers:	DAN, INW, LAN, PUR, SCH
Category:		B

MORPHINE SULFATE
Dosage form(s):	SUSTAINED RELEASE TABLET	Strength(s): 30mg, 60mg, 100mg
Manufacturers:	PUF, ROX
Category:		B

NEOSTIGMINE METHYLSULFATE
Dosage form(s):	INJECTION	Strength(s): 1-1000, 1-2000, 1-4000
Manufacturers:	CMC, ESR, LAN, S-M,
Category:		PRE-38

NITROGLYCERIN
Dosage form(s):	SUBLINGUAL TABLET	Strength(s): 0.3mg, 0.4mg, 0.6mg
Manufacturers:	P/D ETX
Category:		PRE-38

NORTRIPTYLINE HCl
Dosage form(s):	CAPSULE	Strength(s): 10mg, 25mg
Manufacturers:	LIL, SAN
Category:		B

NYLIDRIN
Dosage form(s):	TABLET	Strength(s): 6mg, 12mg
Manufacturers:	GEV, C/P, DAN, ROR, ZGP
Category:		DESI

OPIUM TINCTURE, DEODORIZED
Dosage form(s):	LIQUID	Strength(s): 10% OPIUM
Manufacturers:	HAL, LIL
Category:		PRE-38

PAPAVERINE HCl (NON-SUSTAINED RELEASE)
Dosage form(s):	INJECTION	Strength(s): 30mg/ml
CAPSULE	75mg, 150mg, 300mg
TABLET	30mg, 60mg, 100mg, 150mg, 200mg, 300mg
Manufacturers:	CHE, CMC, GEV, DAN, HAL, HEA, LAN, LEM, MMD, MYL, PUR, REN, SLV, VAN, EON, ZGP
Category:		PRE-38

PARALDEHYDE
Dosage form(s):	LIQUID	Strength(s): 100%
INJECTION
Manufacturers:	CMC, ESR, 
Category:		PRE-38

PAREGORIC
Dosage form(s):	LIQUID	Strength(s): 2mg MORPHINE EQUIV./5ml
Manufacturers:	APC, BOW, HAL, LAN, LIL, ALP, P/D, PUR, ROX, RPC, STL
Category:		OTC

PENICILLIN G BENZATHINE
Dosage form(s):	INJECTION	Strength(s): 600, 000 UNITS/ml
Manufacturers:	PFI, W-A
Category:		B

PENTAERYTHRITOL TETRANITRATE
Dosage form(s):	TABLET	Strength(s): 10, 20
SUSTAINED ACTION TABLET	80mg
Manufacturers:	COO, GEV, DAN, INW, KIR, MER, P/D, PUR, STA, S-M, ZGP
Category:		DESI

PHENAZOPYRIDINE HCl
Dosage form(s):	TABLET	Strength(s): 100mg, 200mg
Manufacturers:	AMI, BAR, COP, C-P, LAN, P/D, QUA, RIC, S-M, TAB, VAN, 
Category:		PRE-38

PHENOBARBITAL
Dosage form(s):	ELIXIR	Strength(s): 20mg/5ml
TABLET	15mg, 16mg, 30mg, 32mg, 60mg, 65mg, 100mg
Manufacturers:	APC, BAR, BOW, GEV, C/P, DAN, HAL, ICN, INW, LAN, LED, LEM, LIL, MMD,  ALP, P/D, PUR, REX, ROX, RUG, STL, STA, TAB, EON, W-W,  S/W, W-A, ZGP
Category:		PRE-38

PHENYLEPHRINE HCl
Dosage form(s):	SOLUTION	Strength(s): 0.25%, 1%
OPHTHALMIC SOLUTION	0.12, 2.5, 10%
Manufacturers:	AKO, ALC, ALL, ALP, MUR, B&L, PUF, RPC, STS, S/W
Category:		PRE-38

PHENYLPROPANOLAMINE HCl, PHENYLEPHRINE HCl, PHENYLTOLOXAMINE CITRATE, CHLORPHENIRAMINE MALEATE
Dosage form(s):	PEDIATRIC DROPS	Strength(s): 5mg/1.25mg/2mg/0.5mg/ml
PEDIATRIC SYRUP	5mg/1.25mg/2mg/0.5mg/5ml
Manufacturers:	ALP,  APO
Category:		PRE-38

PHYTONADIONE
Dosage form(s):	INJECTION	Strength(s): 2mg, 10mg/ml
Manufacturers:	ABB, ROC, IMS, MCK, SKB
Category:		B

PILOCARPINE HCl
Dosage form(s):	OPHTHALMIC SOLUTION	Strength(s): 0.25%, 0.5%, 1%, 2%, 3%, 4%, 6%, 8%
Manufacturers:	ALC,  CVO, W-A, OPT,  B&L, PRO,  STS
Category:		PRE-38

PIPERAZINE CITRATE
Dosage form(s):	SYRUP	Strength(s): 500mg/5ml
TABLET	250mg, 500mg
Manufacturers:	BLU,ALP, GLW, LAN, SLV, S/W
Category:		PRE-38

POTASSIUM GLUCONATE
Dosage form(s):	LIQUID	Strength(s): 20mEq/15ml
Manufacturers:	ALP, CMC, GEV, LAN, LED, , RAH, ROX, RPC, S-M, 
 Category:		B

POTASSIUM IODIDE
Dosage form(s):	LIQUID	Strength(s): SATURATED SOLUTION
Manufacturers:	ALP, CMC, GEN, GEV, P/R, ROX, RPC, STL, , USL
Category:		PRE-38

PREDNISOLONE ACETATE
Dosage form(s):	INJECTION	Strength(s): 25, 50, 100mg/ml
Manufacturers:	ALC, ALL, CTL, STS, LEM, B&L, SCH
Category:		B

PREDNISOLONE TEBUTATE
Dosage form(s):	INJECTION	Strength(s): 20mg/ml
Manufacturers:	ALP, FOY, RBP, MCK
Category:		B

PROBENECID W/ COLCHICINE
Dosage form(s):	TABLET	Strength(s): 500mg/0.5mg
Manufacturers:	DAN, LEM, MCK, RIC, ZGP
Category:		B

PROMETHAZINE HCl
Dosage form(s):	TABLET	Strength(s): 12.5mg, 25mg, 50mg
Manufacturers:	ALL, ALT, ALP, DAN, ESR, GEV, KNO, KVN, LEM, LIF, MSM, RPC, S/W, W-A
Category:		B

PROPYLTHIOURACIL
Dosage form(s):	TABLET	Strength(s): 50mg
Manufacturers:	ANA, KNO, CHE, DAN, LIL, HAL, LAN, LED, P/D, PUR, RIC, TAB, W-W, ZEN
Category:		B

PSEUDOEPHEDRINE HCl
Dosage form(s):	LIQUID	Strength(s): 30mg/5ml
TABLET	30mg, 60mg
SUSTAINED RELEASE CAPSULE	120mg
Manufacturers:	ALP, BOW, GLW, CEN, CHE, GEV, DAN, HAL, RBP, LEM, MMD, PAR, ROX, SLV, SUP
Category:		OTC

PSEUDOEPHEDRINE HCl, CHLORPHENIRAMINE MALEATE
Dosage form(s):	TABLET	Strength(s): 60mg/4mg
Manufacturers:	BER, GLW, ROR, SCH, SKB
Category:		OTC

PSEUDOEPHEDRINE SULFATE, DEXBROMPHENIRAMINE MALEATE
Dosage form(s):	SUSTAINED RELEASE TABLET	Strength(s): 120mg/6mg
Manufacturers:	COP, GEV, SCH
Category:		OTC

QUININE SULFATE
Dosage form(s):	TABLET	Strength(s): 260mg
Manufacturers:	CHE, GEV, MMD
Category:		PRE-38

RAUWOLFIA SERPENTINA
Dosage form(s):	TABLET	Strength(s): 50mg, 100mg
Manufacturers:	BOW, CMB, GEV, DAN, FER, HAL, ICN, KIR, PAN, PPI, PRI, BMS,  SLV, RIC, TAB, VAL, ZEN
Category:		B

RESERPINE
Dosage form(s):	TABLET	Strength(s): 0.1mg, 0.25mg, 0.5mg, 1.0mg
INJECTION
Manufacturers:	BEL, BMS, BOW, CMB, GEV, DAN, FER, GEI, GEN, HAL, ICN, , KIR, LAN, LEM, LIL, MKL, MYL, PAN, PRV, PRI, PUR,  SLV, REX, RIC, ROX, STL, TAB, P/U, VAL, ZEN
Category:		B

SALSALATE
 Dosage form(s):	TABLET	Strength(s): 500mg, 750mg
Manufacturers:	GEV,  3MP, SID
Category:		Pre-38

SODIUM FLUORIDE
Dosage form(s):	TABLET	Strength(s): 0.55mg, 1.1mg, 2.2mg (NaF)
DROPS	0.125mg (F-)/DROP
CHEWABLE TABLET	0.55mg, 1.1mg, 2.2mg (NaF)
Manufacturers:	ABL, KNO, BOW, CHE, CMC, COP, C-P, GEN, HOY, KIR, RIC, RUG, STL,
Category:		PRE-38

SULFAMETHOXAZOLE, PHENAZOPYRIDINE HCl
 Dosage form(s):	TABLET	Strength(s): 500/100mg
Manufacturers:	COP, RIC
Category:		DESI

SULFASALAZINE
Dosage form(s):	ENTERIC COATED TABLETS	Strength(s): 500mg
Manufacturers:	DAN, LED, LEM, MUT, KBP, ROW, SUP, VIP
Category:		B

SULFISOXAZOLE PHENAZOPYRIDINE HCl
Dosage form(s):	TABLET	Strength(s): 500/50mg
Manufacturers:	COP, KAY, ROC, ROX, SLV, S-M, STN, VAN,
Category:		DESI

TERBUTALINE SULFATE
Dosage form(s):	TABLET	Strength(s): 2.5mg, 5mg
Manufacturers:	GEI, MMD
Category:		B

TESTOSTERONE
Dosage form(s):	INJECTION	Strength(s): 25mg/ml, 50mg/ml, 100mg/ml
Manufacturers:	BAT, STS,RBP, LIL, MAY
Category:		PRE-38

TETRACAINE HCl
Dosage form(s):	OPHTHALMIC SOLUTION	Strength(s): 0.5%
Manufacturers:	ALC, GEN, B&L, S-M, S/W 
Category:		PRE-38

THEOPHYLLINE (NON-SUSTAINED RELEASE)
Dosage form(s):	CAPSULE	Strength(s): 100mg, 200mg
TABLET	100, 125, 200, 225, 250mg
Manufacturers:	ALP, BEL, BER, CNC, CTL, FER, HAL, KNO, LAN, LIF, MMD, PAN, P/A, RIC, 3MP, ROR, ROX, RPC, SEA, 
Category:		B

THEOPHYLLINE, GUAIFENESIN
Dosage form(s):	ELIXIR	Strength(s): 150mg/90mg/15ml
LIQUID
Manufacturers:	MEA, RPC
Category:		PRE-38

THEOPHYLLINE, POTASSIUM IODIDE (THEOPHYLLINE, POTASSIUM IODIDE, ALCOHOL)
Dosage form(s):	ELIXIR	Strength(s): 80mg/130mg/10%/15ml
Manufacturers:	FOR, ALP, RPC
Category:		PRE-38

THYROGLOBULIN
Dosage form(s):	TABLET	Strength(s): 65mg
Manufacturers:	RIC, P/D, W-L
Category:		B

TRIAMCINOLONE DIACETATE
Dosage form(s):	INJECTION	Strength(s): 25mg, 40mg/ml
Manufacturers:	BMS, LED, LEM, STS
Category:		B

TRICHLORMETHIAZIDE, RESERPINE
Dosage form(s):	TABLET	Strength(s): 4mg/0.1mg
Manufacturers:	MMD, SCH
Category:		B

TRIPROLIDINE HCl, PSEUDOEPHEDRINE HCl
Dosage form(s):	TABLET	Strength(s): 2.5mg/60mg
SYRUP	1.25mg/30mg/5ml
Manufacturers:	GLW, ALP, CHE, CNC, GEV, HAL, ICN, LED, LEM, LIF, NEW, B&L, PRI, PUR, ROX, SLV, SUP, VAN, ZEN
Category:		OTC

TRYPSIN, BALSAM PERU, CASTOR OIL
Dosage form(s):	TOPICAL AEROSOL	Strength(s): 0.1mg/72.5mg/650mg IN EACH 0.82CC SPRAY
Manufacturers:	COP, HIC
Category:		PRE-38

	PARTIAL PROPRIETARY BRAND CROSS-REFERENCE

Generically equivalent drug products in the same strength and dosage form listed in the Additional List are interchangeable if their respective manufacturers are listed for that product. This partial cross-reference section does not attempt to list all brand names which are approved for interchange. For most products only one, usually the innovator or most commonly prescribed brand, is listed below for quick reference purposes.
See page 4105 for precise instructions for determining the interchangeability of drug products.

BRAND	SEE
(ATROPINE SULFATE, HYOSCINE HBr, HYOSCYAMINE HBr, PHENOBARBITAL)
(THEOPHYLLINE, POTASSIUM IODIDE, ALCOHOL)
ACTIFED	TRIPROLIDINE HCl, PSEUDOEPHEDRINE HCl
ANDROID	METHYLTESTOSTERONE
ANTABUSE DISULFIRAM
AQUAMEPHYTON	PHYTONADIONE
AURALGAN	BENZOCAINE, ANTIPYRINE
AZO-GANTANOL	SULFAMETHOXAZOLE, PHENAZOPYRIDINE
AZO-GANTRISIN	SULFISOXAZOLE PHENAZOPYRIDINE HCl
AZULFADINE	SULFASALAZINE
BENADRYL	DIPHENHYDRAMINE HCl
CYANOCOBALAMIN
BICILLIN	PENICILLIN G BENZATHINE
BRETHINE	TERBUTALINE SULFATE
CHLOR-TRIMETON	CHLORPHENIRAMINE MALEATE
COL-BENEMID	PROBENECID W/ COLCHICINE
CYCLANDELATE
DECADRON	DEXAMETHASONE
DESQUAM	BENZOYL PEROXIDE
DIMETANE DX	BROMPHENIRAMINE, DEXTROMETHORPHAN, PSEUDOEPHEDRINE
DIUPRESS	CHLOROTHIAZIDE W/ RESERPINE
DONNATAL	ATROPINE SULFATE COMPOUND
DRAMAMINE	DIMENHYDRINATE
DRIXORAL	(product reformulated)
ECONOPRED	PREDNISOLONE ACETATE
ELIXOPHYLLINE KI	THEOPHYLLINE, POTASSIUM IODIDE
EMPIRIN W/ CODEINE	ASPIRIN W/ CODEINE PHOSPHATE
ESTINYL	ETHINYL ESTRADIOL
EXNA	BENZTHIAZIDE
FEDAHIST	PSEUDOEPHEDRINE HCl, CHLORPHENIRAMINE MALEATE
GLAUCON	EPINEPHRINE HCl
GRANULEX	TRYPSIN, BALSAM PERU, CASTOR OIL
HALOTESTIN	FLUOX\YMESTERONE
HYCOMINE	HYDROCODONE BITARTRATE W/ PHENYLPROPANOLAMINE
HYDROPRES	HYDROCHLOROTHIAZIDE W/ RESERPINE
ISOPTO CARPINE	PILOCARPINE HCl
ISORDIL TEMBID	ISOSORBIDE DINITRATE
ISUPREL	ISOPROTERENOL HCl
KAON	POTASSIUM GLUCONATE
KENALOG	TRIAMCINOLONE DIACETATE
LARODOPA	LEVODOPA
LEVSIN	L-HYOSCYAMINE SULFATE
LIBRAX	CHLORDIAZEPOXIDE W/CLIDINIUM BROMIDE
MANDELAMINE	METHENAMINE MANDELATE
MEBARAL	MEPHOBARBITAL
MENEST	ESTROGENS, ESTERIFIED
METALONE T.B.A	PREDNISOLONE TEBUTATE
MICRONASE	GLYBURIDE
MAGNESIUM SALICYLATE
NEO-SYNEPHRINE	PHENYLEPHRINE HCl
CHLORAL HYDRATE
PAMELOR	NORTRIPTYLINE HCl
PHENERGAN PLAIN	PROMETHAZINE HCl
PONTOCAINE	TETRACAINE HCl

PROSED	METHENAMINE COMBINATION (METHENAMINE, PHENYLSALICYLATE, 
	ATROPINE SULFATE, HYOSCYAMINE, BENZOIC ACID METHYLENE BLUE)

PROSTIGMINE	NEOSTIGMINE METHYLSULFATE
PYRIDIUM	PHENAZOPYRIDINE HCl
QUINAMM	QUININE SULFATE
SALUTENSIN	HYDROFLUMETHIAZIDE, RESERPINE
SANOREX	MAZINDOL
SERAPES	HYDRALAZINE HCl, HYDROCHLOROTHIAZIDE, RESERPINE
SLO-PHYLLIN GG	THEOPHYLLINE, GUAIFENESIN
SLO-PHYLLIN	THEOPHYLLINE (NON-SUSTAINED RELEASE)
SSKI	POTASSIUM IODIDE
SUDAFED	PSEUDOEPHEDRINE HCl
SYNTHROID	LEVOTHYROXINE SODIUM
TENUATE	DIETHYLPROPION HCl
TESTOSTERONE
TUINAL	AMOBARBITAL SODIUM, SECOBARBITAL SODIUM
VASODILAN	ISOXSUPRINE

(PAGES 4127 THROUGH 4132 ARE RESERVED FOR FUTURE USE.)

8/31/01	105 CMR ‑

8/31/01	105 CMR - 4118.

8/16/02	105 CMR -